DOCSLIB.ORG

Interview: Alice and Nancy Wexler Hdbuzz Interviews Alice and Nancy Wexler, the Sisters at the Heart of the Hereditary Disease Foundation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interview: Alice and Nancy Wexler Hdbuzz Interviews Alice and Nancy Wexler, the Sisters at the Heart of the Hereditary Disease Foundation Interview: Alice and Nancy Wexler HDBuzz interviews Alice and Nancy Wexler, the sisters at the heart of the Hereditary Disease Foundation By Professor Ed Wild October 20, 2012 Edited by Dr Jeff Carroll he Hereditary Disease Foundation, or HDF, is a key player in the world of Huntington’s disease research. At the HDF’s recent biennial scientific meeting in T Cambridge, Massachusetts - ‘The Milton Wexler Celebration of Life and Creativity’ - HDBuzz met Nancy and Alice Wexler, the remarkable sisters at the heart of the HDF’s work. The Wexlers The story of the HDF is intertwined with the story of Nancy and Alice Wexler’s lives. Alice and Nancy Wexler Image credit: Alice Wexler Nancy was 23, and Alice 26, when their father Milton, a prominent psychoanalyst, told them their mother Leonore had been diagnosed with Huntington’s disease in 1968. As it always is, the news was a bombshell. Milton was not one to take such news lying down, however. He approached Marjorie Guthrie, wife of folk singer Woody Guthrie. Marjorie had established the Committee to Combat Huntington’s Disease after Woody had died of HD the previous year. “Dad was always interested in research, and wanted to recruit scientists to get interested in doing research on Huntington’s,” recalls Alice. 1 / 6 It was a daunting task: the scientific landscape was dramatically different back then, says Nancy. “In 1968 nobody had even heard of Huntington’s disease, and very few people did research on it. And when we started to look for people to interest in research, it was extremely difficult to get people interested”. Alice, a historian and writer, whose books on Huntington’s disease include ‘The Woman Who Walked into the Sea’ and ‘Mapping Fate’, adds, “There was actually a fair amount of research going on earlier, but one problem was that much of it was aimed at identifying people who were going to get it, in order to stop them from having children.” HDF’s workshops Undeterred, Milton established the Hereditary Disease Foundation as a non-profit organization, and set out to produce a significant shift in how Huntington’s disease was viewed and studied. That remains the mission of his daughters and the HDF’s expert Scientific Advisory Board. Where to begin? Get people talking. Drawing on his background as a psychotherapist, Milton organized a series of workshops - small meetings of scientists from different fields, discussing HD and exchanging ideas freely. The HDF’s workshops - which continue to this day - always began with an introductory talk to the scientists from an HD family member. “Huntington’s is a very obscure disease in a lot of ways,” explains Nancy. “Even doctors who treat HD patients don’t actually have a conversation with them one to one as a human being. And we felt that that was critical. People would get motivated, people would get passionate.” HDF workshops have unique rules to encourage creative thinking by scientists. “They had to be small,” says Nancy. “Fifteen to twenty people,” adds Alice. Slides and Powerpoint presentations are banned, too, drawing the participants out of their comfort zones. “Everybody is freaked out about that, but it gets people to focus on what actually matters in the research, and what matters about the data,” says Nancy. The HDF was instrumental in bringing some big names into the Huntington’s disease field, including several Nobel Prize winners. But the sisters agree that attracting and supporting young researchers has always been key. “That was a big focus - to find young people, people who were just starting their careers, and to get them to be interested in Huntington’s,” recalls Alice. Recruiting young researchers goes beyond the number of years ahead of them - they are free from prejudices and preconceived notions about how to approach problems, too. Nancy, an irrepressible storyteller, slips into an affectionate parody of a senior researcher holding forth at an early workshop: “Well, this meeting’s going to go on for half an hour, after which we’re going to get the revealed truth, and then - nothing’s going to happen!” But 2 / 6 the younger researchers had no such fatalism - “no sense of what was impossible,” as Nancy puts it. The marker, the gene and beyond The emphasis on unfettered thinking and using the brightest minds to strive towards the seemingly impossible has created an impressive array of HDF-supported scientific progress. The discovery of a DNA marker for Huntington’s disease in 1983, and the HD gene itself in 1993, were accelerated by the Foundation’s workshops, organization and funding. “Finding the marker was radical; that absolutely changed the planet,” Nancy jokes - but it’s not far from the truth: the DNA marker focused the search for the HD gene. And from the HD gene we get our entire understanding of how HD causes damage, and the large repertoire of treatment targets we now have. Beyond HD, the efforts of the “gene hunters” were central to the revolution in genetics that we hope will eventually yield treatments for many diseases including Huntington’s. “The gene hunters invented about fourteen technologies en route,” says Nancy. Nancy is also behind the Venezuela Project - a 32-year study based in an area of that country where HD happens to be many times more common than elsewhere. Hundreds of related volunteers from those villages participated in the research that led to finding the marker and the gene. DNA from the Venezuela Project was also used to discover that CAG repeat length - the number of ‘stutters’ in a person’s HD gene - can affect the age when a person is likely to develop HD symptoms. “A big focus was to find young people, and to get them to be interested in Huntington’s ” Since the gene was found, HDF-supported work has led to some big advances. In 1996, Gill Bates of King’s College London developed the first HD mouse model. Called the ‘R6/2’, Bates' mice have taught us lots about how the HD mutation causes damage, and are still used today to study the disease and test possible treatments. Bates unexpectedly found clumps of protein, called ‘aggregates’, in the brains of her mice. “Nobody thought that Huntington’s had aggregates,” recalls Nancy, but spurred on by the mouse discovery, these aggregates were soon shown to be an important change found in HD patient brains, too. Another game-changing moment was the 2000 study by Ai Yamamoto, who bred an HD mouse in which the abnormal gene could be artificially ‘switched off’. To everyone’s surprise, switching off the gene allowed mice that had already developed symptoms to get better. Nancy is particularly pleased to recall that breakthrough, because the HDF had nurtured Yamamoto from early in her career. “We funded her to do her graduate work. She didn’t even have a doctorate!” she laughs. Yamamoto’s work paved the way for the gene silencing or huntingtin lowering treatments that are now close to being tested in Huntington’s disease. In 2002, the HDF held the first 3 / 6 workshop on using RNA-based drugs to ‘switch off’ the HD gene, and HDF-supported researchers like Beverly Davidson - whom we recently interviewed for our ‘EuroBuzz’ feature - remain central to advancing those treatments to clinical trials as quickly and safely as possible. Today and tomorrow After the discovery of the gene, why has Huntington’s disease has proven such a tough nut to crack? “Biology is really complicated; we’re really complicated, our cells are really complicated,” explains Nancy. “Every time you look under a rock for what the Huntington gene’s doing, you find something fascinating and interesting, maybe relevant and maybe not. And so even figuring out what’s relevant is tricky.” Nancy challenges an oft-mentioned piece of conventional wisdom in the HD field - the idea that we’ve ‘cured the mice’ in many different ways, and the problem now is ‘translating’ those successes into human patients. “I think that we haven’t had very much success in models, frankly. One thing that did work was gene silencing in mice.” One success Nancy considers convincing is a drug called SAHA, which Gill Bates first tested on HD mice in an HDF-supported study in 2002. The SAHA story is a good example of why progress in science can feel so painfully slow to the people waiting for the big breakthroughs. SAHA was thought to restore normal gene switching, which goes wrong in HD. “The mice got better. And they improved their grip strength and they improved survival a little bit. But SAHA’s toxic. Gill dedicated years of her life to studying how it worked.” Ten years later, Bates presented the latest results of her work at the HDF meeting where we met the Wexlers. “She just figured out it works by doing something in the cell - not in the nucleus where the DNA is. And she just presented that at our meeting, ten years later. And Gill does more work than anyone I’ve ever met in my life!” It’s a vivid example of how long it can take from a discovery, to a fuller understanding of the mechanisms behind it. So, bearing in mind the amount of work to be done, and the optimism surrounding recent progress towards effective treatments for Huntington’s disease, what’s the HDF’s focus for the near future? “Push the envelope,” volunteers Nancy with characteristic enthusiasm. “We try not to put all of our eggs in one basket,” adds Alice, “but also to not be all over the place.
Load more

Recommended publications
  • Anne Buckingham Young
    BK-SFN-NEUROSCIENCE-131211-13_Young.indd 554 17/04/14 2:26 PM Anne Buckingham Young BORN: Evanston, Illinois December 30, 1947 EDUCATION: Vassar College, Summa Cum Laude, AB (1969) Johns Hopkins University Medical School, MD (1973) Johns Hopkins University Medical School, PhD (1974) APPOINTMENTS: Assistant, Full Professor of Neurology, University of Michigan (1978–1991) Julieanne Dorn Professor of Neurology, Harvard Medical School (1991–2012) Chief, Neurology Service, Massachusetts General Hospital (1991–2012) Distinguished Julieanne Dorn Professor of Neurology, Harvard Medical School (2012–present) HONORS AND AWARDS (SELECTED): Member, Institute of Medicine (1994) Fellow, American Academy of Arts and Sciences (1995) Dean’s Award for Support and Advancement of Women Faculty, Harvard Medical School (1999) Marion Spence Faye Award for Women in Medicine (2001) President, American Neurological Association (2001–2003) President, Society for Neuroscience (2003–2004) Fellow, Royal College of Physicians, England (2005) Milton Wexler Award, Hereditary Disease Foundation (2006) Johns Hopkins Medical School Distinguished Alumni Award (2007) Vassar College Distinguished Alumni Award (2010) As a graduate student, Young provided the first biochemical evidence of glutamate as a neurotransmitter of the cerebellar granule cells. She developed biochemical techniques to measure inhibitory amino acid neurotransmitter receptors in the mammalian brain and spinal cord. As a faculty member at the University of Michigan, Young and her late husband (John B. Penney, Jr.) established the first biochemical data that glutamate was the neurotransmitter of the corticostriatal, corticobulbar, and corticospinal pathways. They developed film-based techniques for quantitative receptor autoradiography. They also provided evidence for their most widely cited model of basal ganglia function.
    [Show full text]
  • TPWKY This Is Exactly Right
    TPWKY This is Exactly Right. Jay My name is Jay and I am 34 years old and I was recently diagnosed with Huntington's disease. My grandfather was diagnosed with Huntington's in his 80s but I don't think he and my grandmother really understood the severity of the illness and its implications for their children and grandchildren. So they never really told us until my father started seeing some symptoms in his 50s. So that's when I found out, I guess I was 28, I'd just been married, you know there's so much optimism and then I find out from my parents that there's this terrible shadow, you know, that's going to be potentially hanging over my life. And it was definitely really, really hard, I'm not gonna lie. Your priorities sort of shift, just trying to maximize the years that you might have with a good quality of life, you know. So I didn't get tested right away, I really wasn't ready. But over the years I started to I guess come to a point of acceptance and I also started to see symptoms starting to appear. Things like coordination issues, balance issues also, difficulty swallowing and drinking. So that's how it's starting to affect me and it got to a point where I was ready to be tested. And so I did that I guess a few months ago actually and now I have the official results that I am positive for Huntington's disease. At that point I guess it wasn't as bad as I thought actually to get those words.
    [Show full text]
  • An Interview with Dr. Nancy Wexler: Discovering the Huntington Disease Gene By: Kristin Darwin One Morning in 1968, Dr
    InsightsTM HD periodical A Huntington disease research Issue No 3 -- Fall 2012 Research Round-Up Antisense Meet Isis HD Research in Chile Dr. Lise Munsie Oligoneucleotides Pharmaceuticals Dr. Claudio Hetz and overviews recent Dr. Emily Mitchell Senior Vice President Dr. Rene Vidal discuss developments in HD Sontag overviews the Dr. C. Frank Bennett interventions that may research. CHDI Highlights promises and discusses the company’s alleviate secretory Page 3 Notes on this year’s challenges of using drug development pathway stress in HD. presentations at the Status Report: ASOs for gene efforts using ASOs. Page 11 CHDI HD Clinical Trials silencing. Page 8 Therapeutics At a glance Page 6 Conference in Palm information on Springs, California. current clinical trials Page 4 in HD. Page 5 An Interview with Dr. Nancy Wexler: Discovering the Huntington Disease Gene By: Kristin Darwin One morning in 1968, Dr. Nancy Wexler’s mother, Leonore Wexler, had jury duty in downtown Los Angeles. As Leonore crossed the street on the way to the courthouse, a policeman yelled to her, “How can you be drunk so early in the morning?” Leonore realized that she had been staggering – an obvious sign that something was wrong. Soon after, Leonore was diagnosed with Huntington disease (HD). Nancy Wexler, who was pursuing a PhD in clinical psychology at the time of her mother’s diagnosis, devoted her life to the study of HD. In 1979, Wexler and her colleagues began a research project in Venezuela to search for the HD gene. They surmised that finding the gene was the most direct route to the development of treatments, even cures! They developed a pedigree of over 18,000 individuals and collected more than 4,000 blood samples from the largest extended family with HD ever to have been discovered.
    [Show full text]
  • Bulletin Vol
    american academy of arts & sciences winter 2006 Bulletin vol. lix, no. 2 Page 1 American Academy Welcomes the 225th Class of Members Page 2 Exhibit from the Archives Members’ Letters of Acceptance Page 26 Concepts of Justice Essays by Alan Brinkley, Kathleen M. Sullivan, Geoffrey Stone, Patricia M. Wald, Charles Fried, and Kim Lane Scheppele inside: Projects and Studies, Page 15 Visiting Scholars Program, Page 24 New Members: Class of 2005, Page 42 From the Archives, Page 60 Calendar of Events Thursday, Saturday, February 9, 2006 March 18, 2006 Stated Meeting–Cambridge Stated Meeting–San Francisco “Tax Reform: Current Problems, Possible “Innovation: The Creative Blending of Art Contents Solutions, and Unresolved Questions” and Science” Speaker: James Poterba, mit Speaker: George Lucas, Lucas½lm Ltd. Academy News Introduction and Response: Michael J. Introduction: F. Warren Hellman, Graetz, Yale University Hellman & Friedman, LLC Academy Inducts 225th Class 1 Location: House of the Academy Location: Letterman Digital Arts Center, The Presidio of San Francisco Major Funding from the Mellon Time: 6:00 p.m. Foundation 1 Time: 5:00 p.m. Exhibit from the Academy’s Archives 2 Wednesday, February 15, 2006 Tuesday, April 4, 2006 Challenges Facing the Regional Meeting–Chicago Intellectual Community 7 Stated Meeting and Joint Meeting with “America’s Greatest Lawyer: Abraham Lincoln the Boston Athenæum–Boston in Private Practice and Public Life” Projects and Studies 15 “Great Scienti½c Discoveries of the Twentieth Speaker: Walter E. Dellinger, Century” Duke University Visiting Scholars Program 24 Speaker: Alan Lightman, mit Introduction: Saul Levmore, Academy Lectures University of Chicago Law School Location: Boston Athenæum Location: University of Chicago Law School Time: 6:00 p.m.
    [Show full text]
  • Hgpwexlertranscript.Pdf (121Kb)
    GEORGETOWN UNIVERSITY Joseph and Rose Kennedy Institute of Ethics SUBJECT: Nancy Wexler DATE: INTERVIEWER: Robert Cook-Deegan Q: ...on the grounds of the Banbury Center at Cold Spring Harbor Laboratories, around 1:20 p.m., an interview on the Human Genome Project. I do have a standard set of questions. The first one is to ask you kind of the general context of how you became connected to the Genome Project, what was the first time you heard about it, and what were your responses to it the first time you did hear about it? WEXLER: Hmm. Q: Well, there's an alternative way to get at that, which is where would you trace the roots of the Genome Project, what would you see as the important early events, and how does that relate to your work? Either one of those. WEXLER: Well, there are really two things: one is my own personal involvement with genetic mapping activities that then became the Human Genome Project; and my awareness of Nancy Wexler - page 1 the Human Genome Project as an organized entity, which was rather much later. I think probably the first thing that crossed my awareness that using DNA markers was a possible strategy for finding genes was an incredible letter (which I have to try to find someday) written by Ray White and Arlene Wyman to Miss Alice Pratt, who is the head of the Wills Foundation, which I believe then was the Huntington's Chorea Foundation. It was an old typewriter that had letters missing and was truly hand-pecked out.
    [Show full text]
  • Houses Undergoing Psychoanalysis: Gehry's Residence, Venturi's Mother's House and Johnson's Glass House
    Houses Undergoing Psychoanalysis: Gehry's Residence, Venturi's Mother's House and Johnson's Glass House Ruth Palmon Bachelor of Architecture Bezalel Academy of Art and Design Jerusalem, Israel, 1997 - Submitted to the Department of Architecture in Partial Fulfillment of the requirements for the degree of Master of Science in Architecture Studies At the Massachusetts Institute of Technology June 2002 © 2002 Ruth Palmon. All Rights Reserved The Author hereby grants MIT permission to reproduce and to distribute publicly paper and electronic copies of this thesis document in whole or in part. Signature of Author: Department of Architecture May 23, 2002 Certified by: Julian Beinart Professor of Architecture Thesis Supervisor Accepted by: Julian Beinart Professor of Architecture MASSACHUSETTS INSTITUTE Chairman ,Department Committee on Graduate Students OF TECHNOLOGY JUN 2 4 2002 ROTCH LIBRARIES Mark M. Jarzombek, Associate Professor of History and Architecture, Reader. Beatriz Colomina, Professor of History and Theory of Architecture, Princeton University, Reader. 2 Houses Undergoing Psychoanalysis: Johnson's Glass House, Venturi's Mother's House, and Gehry's Residence. By Ruth Palmon Submitted to the Department of Architecture on May 23, 2002 in Partial Fulfillment of the requirements for the degree of Master of Science in Architecture Studies ABSTRACT The objective of this thesis is to explore the relationship between the self and the house. In approaching the subject, my assumptions were that the basic condition of the house-self relationship is of tension and animosity and that architectural design, following a psychoanalytical tendency to reduce tension, is used to improve this condition. When great amounts of energy and care are invested in this process, the narrative of tension and its resolution is brought to the surface through architectural drawings.
    [Show full text]
  • 0307.1.00.Pdf
    testing knowledge Before you start to read this book, take this moment to think about making a donation to punctum books, an independent non-profit press @ https://punctumbooks.com/support If you’re reading the e-book, you can click on the image below to go directly to our donations site. Any amount, no matter the size, is appreciated and will help us to keep our ship of fools afloat. Contributions from dedi- cated readers will also help us to keep our commons open and to cultivate new work that can’t find a wel- coming port elsewhere. Our adventure is not possible without your support. Vive la Open Access. Fig. 1. Hieronymus Bosch, Ship of Fools (1490–1500) testing knowledge: toward an ecology of diagnosis, Preceded by the dingdingdong Manifesto. Copyright © 2021 by the authors. This work carries a Creative Commons BY-NC-sa 4.0 International li- cense, which means that you are free to copy and redistribute the mate- rial in any medium or format, and you may also remix, transform and build upon the material, as long as you clearly attribute the work to the authors (but not in a way that suggests the authors or punctum books endorses you and your work), you do not use this work for commercial gain in any form whatsoever, and that for any remixing and transfor- mation, you distribute your rebuild under the same license. http://cre- ativecommons.org/licenses/by-nc-sa/4.0/ First published in 2012 (The Dingdingdong Manifesto) and 2015 (Testing Knowledge) by Éditions Dingdingdong.
    [Show full text]
  • A Physician's Guide to the Management of Huntington's Disease
    A Physician’s Guide to the Management of Huntington’s Disease Third Edition Martha Nance, M.D. Jane S. Paulsen, Ph.D. Adam Rosenblatt, M.D. Vicki Wheelock, M.D. Front Cover Image: Volumetric 3 Tesla MRI scan from an individual carrying the HD mutation, with full manifestation of the disease. The scan shows atrophy of the caudate. Acknowledgements: Images were acquired as part of the TRACK-HD study of which Professor Sarah Tabrizi is the Principal Investigator. TRACK-HD is funded by CHDI Foundation, Inc., a not-for-profit organization dedicated to funding treatments for Huntington¹s disease. A Physician’s Guide to the Management of Huntington’s Disease Third Edition Martha Nance, M.D. Director, HDSA Center of Excellence at Hennepin County Medical Center Medical Director, Struthers Parkinson’s Center, Minneapolis, MN Adjunct Professor, Department of Neurology, University of Minnesota Jane S. Paulsen, Ph.D. Director HDSA Center of Excellence at the University of Iowa Professor of Neurology, Psychiatry, Psychology, and Neuroscience, University of Iowa Carver College of Medicine, Iowa City, IA Principal Investigator, PREDICT-HD, Study of Early Markers in HD Adam Rosenblatt, M.D. Director, HDSA Center of Excellence at Johns Hopkins, Baltimore Maryland Associate Professor of Psychiatry, and Director of Neuropsychiatry, Johns Hopkins University School of Medicine Vicki Wheelock, M.D. Director, HDSA Center of Excellence at University of California Clinical Professor, Neurology, University of California, Davis Medical Center, Sacramento, CA Site Investigator, Huntington Study Group Editors: Debra Lovecky Director of Programs, Services & Advocacy, HDSA Karen Tarapata Designer: J&R Graphics Printed with funding from an educational grant provided by 1 Disclaimer The indications and dosages of drugs in this book have either been recommended in the medical literature or conform to the practices of physicians’ expert in the care of people with Huntington’s Disease.
    [Show full text]
  • Lundbeck Launches Fourth Annual Build Hope for Huntington's
    FOR IMMEDIATE RELEASE Lundbeck Launches Fourth Annual Build Hope for Huntington’s Disease Campaign in Partnership with the Hereditary Disease Foundation Campaign helps support a clinic vital to the Huntington’s disease community and genetic research Deerfield, Ill. November 12, 2013 – Today, Lundbeck and the Hereditary Disease Foundation announced the launch of the fourth annual Build Hope for HD initiative. The online donation campaign helps generate support for the Casa Hogar Corea de Huntington Amor y Fe (Huntington’s Chorea Home of Love and Faith), a unique Venezuelan clinic serving the families who made possible groundbreaking discoveries in Huntington’s disease (HD) and other genetic diseases. To trigger a donation from Lundbeck to help keep this vital clinic open, visit www.BuildHopeforHD.com or www.hdfoundation.org and click on the campaign icon before the end of the year. For every click, Lundbeck will donate $15 to the clinic, up to $25,000. The Build Hope for HD campaign celebrates an especially important milestone for the HD community this year. Thirty years ago, scientists supported by the Hereditary Disease Foundation successfully discovered the location of the HD gene using DNA markers.1 This was the first time scientists used DNA markers to discover any gene. Ten years later, the Gene Hunters – 100 brilliant scientists supported by the Hereditary Disease Foundation – discovered the HD gene itself.2 A group of families living along the shores of Lake Maracaibo, Venezuela, were critical to these groundbreaking scientific breakthroughs. It is because of their generosity and collaboration that the HD marker and gene were found.
    [Show full text]
  • Huntington Disease: a Journey Through History Review
    Review Neurosciences and History 2016; 4(4): 160-163 Huntington disease: a journey through history E. Cubo Department of Neurology. Hospital Universitario de Burgos, Burgos, Spain. ABSTRACT The story of Huntington disease takes us on a fascinating journey through history. Initially, the Ancient Greek word choreia was used to describe a functional movement disorder, a strange dance observed in people gripped by hysteria at the height of the bubonic plague epidemic in medieval Europe. The first descriptions of this hereditary neurodegenerative disease were formulated in the 19th century, with the causal gene being identified in 1993. Neu - rologists including Charcot, Gowers, Lund, and, finally, George Huntington made highly valuable contributions in the description of the disease. The contribution of the Venezuelan neurologist Américo Negrette, who drew attention to a community in Maracaibo which had an unusually high prevalence of Huntington disease, was crucial in sparking scientific interest in the condition. Cases of Huntington disease have now been described worldwide, due to its migration first across Europe and subsequently across other continents. No cure has been found to date, but the recent advancements in biotechnology mean that silencing the affected gene could become a reality in the near future. KEYWORDS Huntington disease, chorea, Américo Negrette, dancing mania, HTT gene Introduction culously” healing Diocletian’s son of epilepsy. In 1418, Saint Vitus (sometimes also called Saint Guy) was called The term chorea comes from the Greek word choreia , upon to cure people affected by chorea; from that time he meaning “dance”. Chorea, or “dancing mania”, as it was has been appointed the specific saint for that disease.
    [Show full text]
  • Interview with William Dreyer
    WILLIAM J. DREYER (1928–2004) INTERVIEWED BY SHIRLEY K. COHEN February 18th–March 2, 1999 .Photo be Robert Paz, Caltech ARCHIVES CALIFORNIA INSTITUTE OF TECHNOLOGY Pasadena, California Subject area Biology, immunology, biochemistry Abstract An interview in five sessions in 1999 with William J. Dreyer, molecular immunologist and Caltech professor of biology (1963-2004). He begins with a discussion of how some people think visually, himself included—a theme to which he returns repeatedly in the interview. He speaks of his family history: childhood in Michigan and Wisconsin; his Norwegian father and possible inherited family traits including dyslexia and mental imaging. Recalls his education at Reed College in Oregon (BA chemistry, 1952) and graduate study at University of Washington (PhD in biochemistry, 1956); works under H. Neurath at UW. First occurrence of cancer while in graduate school. He goes to National Institutes of Health (NIH) as a National Polio Foundation postdoc, where he works on proteins with C. Anfinsen; becomes research scientist at NIH; assists M. Nirenberg in work on genetic code. Meets and works with G. Streisinger on genetic mapping with phage. Still at NIH begins inventing machinery for automating biochemical analyses. Recruited to Caltech and accepts appointment in biology division in 1963. Together with J. Claude Bennett writes major papers on genetic coding for protein http://resolver.caltech.edu/CaltechOH:OH_Dreyer_W structure, gene splicing and monoclonal antibodies. Recalls Leroy Hood’s arrival at Caltech in 1963 as grad student. Dreyer’s consulting work for Spinco division of Beckman Instruments; helps in the design of an automated protein sequencer; his continuing interest in new technologies.
    [Show full text]
  • Thousands Join Lundbeck and the Hereditary Disease Foundation to Build Hope for Huntington’S Disease
    PR283 FOR IMMEDIATE RELEASE CONTACT: Katie White 847-282-1929 Thousands Join Lundbeck and the Hereditary Disease Foundation to Build Hope for Huntington’s Disease Campaign supports families in Venezuela who made possible groundbreaking Huntington’s disease research DEERFIELD, Ill. November 14, 2012 - Today, Lundbeck announced the results of its third annual Build Hope for HD campaign, benefitting the Casa Hogar Amor y Fe (House of Love and Hope), a unique clinic that provides care for people affected by Huntington’s disease (HD). Build Hope for HD, which launched on August 1, 2012, consisted of an online awareness campaign that included an opportunity to click, triggering a donation on BuildHopeforHD.com. Participation from thousands in the HD community and beyond helped spread awareness about this important cause, and resulted in Lundbeck making a donation of $50,000 to the clinic. These funds will allow the clinic to continue to provide treatment, food and medical care to thousands of family members with HD who live along the shores of Lake Maracaibo in Venezuela. “The support from Lundbeck and the HD community allow the Casa Hogar to continue to provide treatment and care to thousands of people affected by HD living around Lake Maracaibo,” said Dr. Nancy Wexler, President of the Hereditary Disease Foundation (HDF) and Higgins Professor of Neuropsychology, Columbia University. “These families are living in extreme circumstances of poverty and duress, and the support from Build Hope helps provide them with basic medical necessities.” Opened in 1999,1 the clinic was built in gratitude to the families whose help was critical to researchers who identified the HD gene in 1983 and isolated it in 1993.2,3 The clinic is now home to over 65 people and provides care and food to many more from the surrounding community.
    [Show full text]